Skip to content

Replimune Group REPL Accrued Compensation

Accrued Compensation at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:AccruedEmployeeBenefitsCurrent.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's accrued compensation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's accrued compensation?
Replimune Group (REPL) reported accrued compensation of $14.44M in Q4 2025.
How has Replimune Group's accrued compensation changed year-over-year?
Replimune Group's accrued compensation decreased by 2.3% year-over-year, from $14.79M to $14.44M.
What is the long-term trend for Replimune Group's accrued compensation?
Over 4 years (2021 to 2025), Replimune Group's accrued compensation has grown at a 50.1% compound annual growth rate (CAGR), from $3.95M to $20.08M.
What does accrued compensation mean?
Employee wages, salaries, bonuses, commissions, and benefits earned but not yet paid as of the reporting date.